Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.69 |
| ▸ | RELA | Q04206 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 2/20 | 0.68 |
| ▸ | MMP9 | P14780 | 3/20 | 0.68 |
| ▸ | MMP8 | P22894 | 3/20 | 0.68 |
| ▸ | MMP2 | P08253 | 2/20 | 0.68 |
| ▸ | MMP13 | P45452 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 3/20 | 0.63 |
| ▸ | MGAM | O43451 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725326 | 0.90 | MMP9 (0.68) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL2702813 | 0.87 | RAB9A (0.64) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL11339575 | 0.87 | KDM4E (0.64) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL23169620 | 0.87 | RAB9A (0.64) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL366824 | 0.86 | RAB9A (0.81) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL29474819 | 0.86 | RAB9A (0.81) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL15774808 | 0.85 | KDM4E (0.63) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 | |
| SCHEMBL31472989 | 0.84 | MMP2 (0.69) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL28608538 | 0.84 | MMP2 (0.69) | KDM4ESMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL754574 | 0.84 | RAB9A (0.73) | KDM4ESMN1; SMN2LMNANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621752-A | Room-temperature phosphorescent waterborne polymer anti-counterfeiting material and preparation method and application thereof | 昆明理工大学 | 2022-06-14 | — | — | CN | claimed |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | claimed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | claimed |
| CN-114621752-B | Room-temperature phosphorescent waterborne polymer anti-counterfeiting material and preparation method and application thereof | 昆明理工大学 | 2022-10-28 | — | — | CN | disclosed |
| CN-114621752-A | Room-temperature phosphorescent waterborne polymer anti-counterfeiting material and preparation method and application thereof | 昆明理工大学 | 2022-06-14 | — | — | CN | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| CN-104030987-A | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA | 2014-09-10 | — | — | CN | disclosed |
| CN-102574786-A | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO SA | 2012-07-11 | — | — | CN | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7495106-B1 | O-aminophenol-containing AB-monomer for heterocyclic rigid-rod polymers | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | disclosed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | disclosed |
| US-4065427-A | Polychromophoric heterocyclic ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4000148-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | KDM4E 1469/4885SMN1; SMN2 2588/4885LMNA 1939/4885 |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | KDM4E 487/4885SMN1; SMN2 1995/4885LMNA 4237/4885 |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | KDM4E 806/4885SMN1; SMN2 3315/4885LMNA 4317/4885 |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | EIF2AK2, CDK15, CDK17 | KDM4E 2008/4885SMN1; SMN2 4393/4885LMNA 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.